Company Overview
Company Type: Public Company
Website: www.nugenmd.com
Number of Employees: -
Ticker: NGMD (TSXV)
Year Founded: -


Business Description
NuGen Medical Devices Inc., a specialty medical device company, focuses on developing and commercializing novel drug delivery technologies in Europe, Asia, and internationally. It offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, semaglutide, and growth and fertility hormone, as well as DNA and conventional/pediatric vaccines. The company also offers InsuJet system that focus on servicing the diabetic community, as well as V5, V6, and V8 InsuJet injectors and sterile accessories. The company was formerly known as BuzBuz Capital Corp. NuGen Medical Devices Inc. is based in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.1
Market Capitalization
28.6
TEV/Total Revenue
NM
EBITDA
(5.3)
Total Enterprise Value
34.6
TEV/EBITDA
NM
EBIT
(5.9)
Cash & ST Invst.
1.3
P/Diluted EPS Before Extra
NM
Net Income
(7.2)
Total Debt
7.2
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
8.9
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Di Benedetto, Anthony 
Executive Chairman
Buzbuzian, Richard 
CEO, President & Director
Laberge, Veronique 
CFO & Secretary
Canton, Nicky 
Chief Operating Officer
Dillon, Elisha 
Head of Global Sales & Strategic Partnerships
Dunlap, Karen 
Interim Chief Customer Officer & Director

Key Board Members
Name
Title
Di Benedetto, Anthony 
Executive Chairman
Buzbuzian, Richard 
CEO, President & Director
Dunlap, Karen 
Interim Chief Customer Officer & Director
Cortese, Philip 
Independent Director
Emerson, Erik 
Member of Advisory Board
Gironda, Greg 
Member of Advisory Board
Irwin, Christopher E.O.
Independent Director
Leombruno, John 
Independent Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
18 King Street East Suite 1400 | Toronto, ON | M5C 1C4 | Canada
Phone: 833-285-2666   

Current and Pending Investors
Care4Pharma B.V.

Prior Investors
Lifeist Wellness Inc. (TSXV:LFST)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.15
Market Cap (mm)
28.6
Open
 0.15
Shares Out. (mm)
197.3
Previous Close
 0.15
Float %
89.5%
Change on Day
0.01
Shares Sold Short (mm)
-
Change % on Day
7.4%
Dividend Yield %
-
Day High/Low
 0.15/ 0.15
Diluted EPS Excl. Extra Items
(0.06)
52 wk High/Low
 0.31/ 0.04
P/Diluted EPS Before Extra
NM
Volume (mm)
0.12
Avg 3M Dly Vlm (mm)
0.59
Beta 5Y
-


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSXV:NGMD - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
BuzBuz Capital Corp.
As of October 19, 2021, BuzBuz Capital Corp. was acquired by Inolife R&D Inc., in a reverse merger transaction.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00
European Pharma Group B.V.
European Pharma Group B.V. operates as a healthcare equipment company. It offers manufacture of medical instruments and supplies (no dental laboratories). It was incorporated in 2010 and is headquartered in Schiphol-Rijk, Netherlands. As of June 5, 2020, European Pharma Group B.V. operates as a subsidiary of NuGen Medical Devices Inc.

Europe
Health Care Equipment
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-18-2023
May-18-2023
Private Placement
Target
NuGen Medical Devices Inc. (TSXV:NGMD)


0.33
Mar-31-2023
Apr-25-2023
Private Placement
Target
NuGen Medical Devices Inc. (TSXV:NGMD)


2.94
Jan-26-2023
Feb-14-2023
Private Placement
Target
NuGen Medical Devices Inc. (TSXV:NGMD)


1.87
Dec-28-2022
Jan-26-2023
Private Placement
Target
NuGen Medical Devices Inc. (TSXV:NGMD)


0.09
Sep-08-2022
Sep-08-2022
Private Placement
Target
NuGen Medical Devices Inc. (TSXV:NGMD)


0.56
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-20-2023
Client Announcements
NuGen Medical Devices Inc. Completes Delivery and First Sale of 500 InsuJet Devices and Consumables in Romania
Sep-20-2023
Company Conference Presentations
NuGen Medical Devices Inc. Presents at Kinvestor Days 2023, Sep-20-2023 09:00 AM
Jul-25-2023
Client Announcements
NuGen Medical Devices Inc. Enters into Distribution Agreement with Sol-Millennium Medical Inc
Jun-23-2023
Executive/Board Changes - Other
NuGen Medical Devices Inc. Announces Executive Changes
Jun-20-2023
Annual General Meeting
NuGen Medical Devices Inc., Annual General Meeting, Jun 20, 2023

M&A Advisors
Dunton Rainville LLP


Advisors
Most Recent Auditor
KPMG Limited
M&A Advisors
Dunton Rainville LLP
Private Placement Advisors
Canaccord Genuity Corp.


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
The Insight Partners
The Insight Partners Research Team
Oct 27, 2022 04:12 AM
NGMD
NuGen Medical Devices in Global Needle Free Injection Systems Market to 2028
Notes
5
Smart Insider Ltd.

Nov 18, 2021 12:29 AM
NGMD
NuGen Medical Devices Inc: 1 director
Reporting Results*
1


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Buzbuzian BA, Richard 

7,217,000

3.66

1.0

Aug-11-2023


Leombruno, John 

5,285,714

2.68

0.8

May-12-2023


N3GU Investments L.P

3,733,333

1.89

0.5

May-11-2022


Di Benedetto, Anthony 

2,312,500

1.17

0.3

Jun-19-2023


Wright, Michael 

769,646

0.39

0.1

Feb-28-2023


Laberge CPA, Veronique 

750,000

0.38

0.1

Jul-31-2023


Irwin B.A., L.L.B., L.L.M., LL.M., LLB, Q.C., Christopher E.O.

460,000

0.23

0.1

Aug-16-2023


Dunlap, Karen 

150,000

0.08

0.0

May-12-2023


Canton, Nicky 

100,000

0.05

0.0

Dec-14-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Buzbuzian BA, Richard 
7,217,000
3,158,500
Leombruno, John 
5,285,714
2,642,857
Laberge CPA, Veronique 
750,000
750,000
Irwin B.A., L.L.B., L.L.M., LL.M., LLB, Q.C., Christopher E.O.
460,000
250,000

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Di Benedetto, Anthony 
2,312,500
(187,500)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Adaptor, InsuJet System, Nanojex Platform, Nanoparticle Powder and Liquid Jet Injector Systems, Nozzle


Upcoming Events
Date/Time
Type
Nov-29-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-20-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
212 KB
Sep-11-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
166 KB
Sep-05-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
319 KB
Aug-29-2023
Jun-30-2023
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
Interim Financial Statements
280 KB
Aug-04-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
206 KB
Jul-25-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
445 KB
Jun-30-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
168 KB
Jun-23-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
Material Change Report
154 KB
Jun-23-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
172 KB
Jun-16-2023
-
NuGen Medical Devices Inc. (TSXV:NGMD)
SEDAR
News Releases
168 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Irwin B.A., L.L.B., L.L.M., LL.M., LLB, Q.C., Christopher E.O. (Independent Director)
Aug-16-2023
Common Shares
250,000
12,607
Derivative Exercise and Retained Stock
119.05
Multiple
Buzbuzian BA, Richard  (CEO, President & Director)
Aug-11-2023
Common Shares
646,000
32,758
Derivative Exercise and Retained Stock
9.83
Multiple
Buzbuzian BA, Richard  (CEO, President & Director)
Aug-09-2023
Common Shares
3,600,000
182,398
Derivative Exercise and Retained Stock
120.79
Multiple
Buzbuzian BA, Richard  (CEO, President & Director)
Aug-08-2023
Common Shares
(197,000)
(33,597)
Open Market Disposition
(2.66)
Multiple
-
Aug-08-2023
Common Shares
(140,000)
(24,081)
Open Market Disposition
-
Exchange Announcement
-
Aug-08-2023
Common Shares
(57,000)
(9,516)
Open Market Disposition
-
Exchange Announcement
Buzbuzian BA, Richard  (CEO, President & Director)
Aug-01-2023
Common Shares
(1,078,000)
(187,837)
Open Market Disposition
(14.08)
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Di Benedetto, Anthony 
Executive Chairman
(416) 791-9399
-

Buzbuzian, Richard 
CEO, President & Director
(647) 501-3290
-

Dunlap, Karen 
Interim Chief Customer Officer & Director
833-285-2666
-

Cortese, Philip 
Independent Director
833-285-2666
-

Emerson, Erik 
Member of Advisory Board
833-285-2666
-

Gironda, Greg 
Member of Advisory Board
833-285-2666
-

Irwin, Christopher E.O.
Independent Director
(416) 361-2516
(416) 361-2519
cirwin@irwinlowy.com
Leombruno, John 
Independent Director
833-285-2666
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Di Benedetto, Anthony 
Executive Chairman
(416) 791-9399
-

Buzbuzian, Richard 
CEO, President & Director
(647) 501-3290
-

Laberge, Veronique 
CFO & Secretary
(514) 831-8626
-

Canton, Nicky 
Chief Operating Officer
833-285-2666
-

Dillon, Elisha 
Head of Global Sales & Strategic Partnerships
833-285-2666
-

Dunlap, Karen 
Interim Chief Customer Officer & Director
833-285-2666
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
